FI3864009T3 - TYK2-kinaasi-inhibiittoreita - Google Patents
TYK2-kinaasi-inhibiittoreita Download PDFInfo
- Publication number
- FI3864009T3 FI3864009T3 FIEP19794095.0T FI19794095T FI3864009T3 FI 3864009 T3 FI3864009 T3 FI 3864009T3 FI 19794095 T FI19794095 T FI 19794095T FI 3864009 T3 FI3864009 T3 FI 3864009T3
- Authority
- FI
- Finland
- Prior art keywords
- compound
- compound according
- hydrogen
- formula
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1816369.1A GB201816369D0 (en) | 2018-10-08 | 2018-10-08 | Pharmaceutical compounds |
| PCT/EP2019/077118 WO2020074461A1 (en) | 2018-10-08 | 2019-10-07 | Tyk2 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3864009T3 true FI3864009T3 (fi) | 2025-03-24 |
Family
ID=64397425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19794095.0T FI3864009T3 (fi) | 2018-10-08 | 2019-10-07 | TYK2-kinaasi-inhibiittoreita |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12187716B2 (https=) |
| EP (1) | EP3864009B1 (https=) |
| JP (1) | JP7383030B2 (https=) |
| KR (1) | KR102844196B1 (https=) |
| CN (1) | CN113056456B (https=) |
| AU (1) | AU2019359320B2 (https=) |
| BR (1) | BR112021006424A2 (https=) |
| CA (1) | CA3111049A1 (https=) |
| DK (1) | DK3864009T3 (https=) |
| ES (1) | ES3021420T3 (https=) |
| FI (1) | FI3864009T3 (https=) |
| GB (1) | GB201816369D0 (https=) |
| IL (1) | IL281599B2 (https=) |
| MX (1) | MX2021003929A (https=) |
| PL (1) | PL3864009T3 (https=) |
| PT (1) | PT3864009T (https=) |
| SG (1) | SG11202102490TA (https=) |
| WO (1) | WO2020074461A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202005114D0 (en) * | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
| JP2024539280A (ja) | 2021-10-25 | 2024-10-28 | カイメラ セラピューティクス， インコーポレイテッド | Ｔｙｋ２分解剤およびそれらの使用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE794096A (fr) | 1972-08-07 | 1973-05-16 | Lepetit Spa | Oxazoles 2,4,5-trisubstitues et leur preparation |
| GB1497536A (en) | 1973-12-17 | 1978-01-12 | Lilly Industries Ltd | 2-acylaminooxazoles methods for their preparation and their use |
| DE19653355A1 (de) | 1996-12-20 | 1998-06-25 | Dresden Arzneimittel | Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung |
| GB0003154D0 (en) | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
| ATE394102T1 (de) | 2000-06-28 | 2008-05-15 | Astrazeneca Ab | Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren |
| CN100400040C (zh) | 2000-10-30 | 2008-07-09 | 詹森药业有限公司 | 三肽酶抑制剂 |
| CA2491895C (en) | 2002-07-09 | 2011-01-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| EP1684750B1 (en) | 2003-10-23 | 2010-04-28 | AB Science | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors |
| GB0504753D0 (en) | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| KR20080066938A (ko) | 2005-10-07 | 2008-07-17 | 깃세이 야쿠힌 고교 가부시키가이샤 | 질소 함유 복소환 화합물 및 그것을 함유하는 의약 조성물 |
| ES2352320T3 (es) | 2006-05-12 | 2011-02-17 | Ab Science | Nuevo procedimiento para la síntesis de compuestos de 2-aminoxazol. |
| US20090093452A1 (en) | 2006-08-24 | 2009-04-09 | Pfizer Inc. | Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| ES2395581T3 (es) | 2007-06-20 | 2013-02-13 | Merck Sharp & Dohme Corp. | Inhibidores de quinasas janus |
| US8278335B2 (en) | 2008-04-21 | 2012-10-02 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
| WO2009155156A1 (en) | 2008-06-18 | 2009-12-23 | Merck & Co., Inc. | Inhibitors of janus kinases |
| EP2310384B1 (en) | 2008-07-09 | 2014-04-09 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| EP2166006A1 (en) | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
| CA2793024A1 (en) | 2010-03-17 | 2011-09-22 | F. Hoffmann-La Roche Ag | Imidazopyridine compounds, compositions and methods of use |
| EP2588105A1 (en) | 2010-07-01 | 2013-05-08 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
| WO2012021611A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US20140228349A1 (en) | 2011-10-12 | 2014-08-14 | Array Biopharma Inc. | 5,7-substituted-imidazo[1,2-c]pyrimidines |
| GB201202027D0 (en) | 2012-02-06 | 2012-03-21 | Sareum Ltd | Pharmaceutical compounds |
| DK2634185T3 (en) | 2012-03-02 | 2016-03-21 | Sareum Ltd | Tyk2 kinase inhibitors |
| KR101202026B1 (ko) | 2012-07-03 | 2012-11-16 | 민호현 | 황토 석부작 제조 방법 |
| MY194668A (en) | 2012-11-08 | 2022-12-12 | Bristol Myers Squibb Co | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses |
| RU2652795C2 (ru) * | 2013-09-03 | 2018-05-03 | Сареум Лимитед | Производные 2-фенил-оксазол-4-карбоксамида, модулирующие активность jak и tyk2 киназ |
| JP6310767B2 (ja) | 2014-05-13 | 2018-04-11 | 日本電子株式会社 | 自動分析装置及びノズル洗浄方法 |
| NO2721710T3 (https=) | 2014-08-21 | 2018-03-31 | ||
| GB201617871D0 (en) | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
| GB202005114D0 (en) | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
-
2018
- 2018-10-08 GB GBGB1816369.1A patent/GB201816369D0/en not_active Ceased
-
2019
- 2019-10-07 US US17/283,151 patent/US12187716B2/en active Active
- 2019-10-07 CN CN201980066166.4A patent/CN113056456B/zh active Active
- 2019-10-07 JP JP2021543577A patent/JP7383030B2/ja active Active
- 2019-10-07 DK DK19794095.0T patent/DK3864009T3/da active
- 2019-10-07 FI FIEP19794095.0T patent/FI3864009T3/fi active
- 2019-10-07 MX MX2021003929A patent/MX2021003929A/es unknown
- 2019-10-07 PL PL19794095.0T patent/PL3864009T3/pl unknown
- 2019-10-07 IL IL281599A patent/IL281599B2/en unknown
- 2019-10-07 WO PCT/EP2019/077118 patent/WO2020074461A1/en not_active Ceased
- 2019-10-07 BR BR112021006424A patent/BR112021006424A2/pt unknown
- 2019-10-07 KR KR1020217013504A patent/KR102844196B1/ko active Active
- 2019-10-07 ES ES19794095T patent/ES3021420T3/es active Active
- 2019-10-07 SG SG11202102490TA patent/SG11202102490TA/en unknown
- 2019-10-07 CA CA3111049A patent/CA3111049A1/en active Pending
- 2019-10-07 PT PT197940950T patent/PT3864009T/pt unknown
- 2019-10-07 AU AU2019359320A patent/AU2019359320B2/en active Active
- 2019-10-07 EP EP19794095.0A patent/EP3864009B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021006424A2 (pt) | 2021-07-06 |
| AU2019359320B2 (en) | 2024-04-04 |
| DK3864009T3 (da) | 2025-03-17 |
| EP3864009A1 (en) | 2021-08-18 |
| CN113056456B (zh) | 2023-06-13 |
| JP7383030B2 (ja) | 2023-11-17 |
| KR102844196B1 (ko) | 2025-08-07 |
| US12187716B2 (en) | 2025-01-07 |
| US20210387981A1 (en) | 2021-12-16 |
| IL281599B1 (en) | 2024-06-01 |
| ES3021420T3 (en) | 2025-05-26 |
| PT3864009T (pt) | 2025-04-23 |
| GB201816369D0 (en) | 2018-11-28 |
| IL281599A (en) | 2021-05-31 |
| CA3111049A1 (en) | 2020-04-16 |
| PL3864009T3 (pl) | 2025-04-22 |
| SG11202102490TA (en) | 2021-04-29 |
| WO2020074461A1 (en) | 2020-04-16 |
| KR20210076036A (ko) | 2021-06-23 |
| EP3864009B1 (en) | 2025-02-19 |
| MX2021003929A (es) | 2021-06-04 |
| CN113056456A (zh) | 2021-06-29 |
| AU2019359320A1 (en) | 2021-03-18 |
| JP2022514799A (ja) | 2022-02-15 |
| IL281599B2 (en) | 2024-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| FI3788047T3 (fi) | Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi | |
| PH12021551792A1 (en) | Bi-ligand drug conjugate and use thereof | |
| JP2018513107A5 (https=) | ||
| MX388457B (es) | Inhibidores de imidazopirazina de la tirosina cinasa de bruton. | |
| FI3307271T3 (fi) | Pyruvaattikinaasin aktivaattorien käyttämisen menetelmä | |
| FI3452039T3 (fi) | Hiustenlähtöhäiriöiden hoito deuteroiduilla JAK-estäjillä | |
| MX2023001468A (es) | Tratamiento de cancer de prostata. | |
| PH12019501802A1 (en) | Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof | |
| FI3801536T3 (fi) | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi | |
| GEP20257716B (en) | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors | |
| FI3840753T3 (fi) | Migalastaatti käytettäväksi fabryn taudin hoitomenetelmissä potilailla joilla on gla-geenin mutaatio | |
| PH12021551541A1 (en) | Compositions and methods for treating neurodegenerative disorders | |
| FI3864009T3 (fi) | TYK2-kinaasi-inhibiittoreita | |
| RU2019125177A (ru) | Новые производные амино-имидазопиридина в качестве ингибиторов янус-киназы и их фармацевтическое применение | |
| RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 | |
| JOP20210019A1 (ar) | شكل جرعة صيدلانية تعطى عن طريق الفم ذات اطلاق مُعدّل | |
| EA201592058A1 (ru) | Применение ландиолола гидрохлорида в длительном лечении тахиаритмии | |
| GB2590189A9 (en) | Lycorine derivatives, pharmaceutical composite thereof and usage therefor | |
| FI3565551T3 (fi) | Menetelmiä bakteeri-infektioiden hoitamiseksi vaborbaktaamin ja meropeneemin yhdistelmällä | |
| BR112023005987A2 (pt) | Composição farmacêutica, preparação farmacêutica, método de tratamento de uma doença ou disfunção associada à atividade de kdm1a em um paciente com sua necessidade, método de inibição de kdm1a e método para suprimir a proliferação de células mieloides malignas em um sujeito com sua necessidade | |
| JOP20240022A1 (ar) | مركبات وتركيبات لعلاج حالات مرتبطة بنشاط sting | |
| FI3697399T3 (fi) | Terapeuttisia aineita käytettäviksi levottomien jalkojen oireyhtymän hoidossa | |
| JP2022514799A5 (https=) | ||
| EP4461362A3 (en) | Nk1-antagonist combination and method for treating synucleinopathies |